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Abstract
Mitotic catastrophe (MC) is an important oncosuppressive mechanism that serves to eliminate cells that become polyploid or
aneuploid due to aberrant mitosis. Previous studies have demonstrated that the activation and catalytic function of caspase-2
are key steps in MC to trigger apoptosis and/or cell cycle arrest of mitotically defective cells. However, the molecular
mechanisms that regulate caspase-2 activation and its function are unclear. Here, we identify six new phosphorylation sites
in caspase-2 and show that a key mitotic kinase, Aurora B kinase (AURKB), phosphorylates caspase-2 at the highly
conserved residue S384. We demonstrate that phosphorylation at S384 blocks caspase-2 catalytic activity and apoptosis
function in response to mitotic insults, without affecting caspase-2 dimerisation. Moreover, molecular modelling suggests
that phosphorylation at S384 may affect substrate binding by caspase-2. We propose that caspase-2 S384 phosphorylation by
AURKB is a key mechanism that controls caspase-2 activation during mitosis.
Introduction
Mitosis is a highly dynamic process that is tightly regulated
by a series of surveillance mechanisms that ensure the faithful
segregation of chromosomes into the nascent daughter cells,
thereby maintaining genomic integrity. Errors in karyokinesis
and/or cytokinesis during cell division generate cells carrying
abnormal genomic content (i.e. aneuploidy or polyploidy) [1].
The chromosomal passenger complex (CPC) is a key factor in
controlling the proper execution of both karyokinesis and
cytokinesis, especially through the activity of its kinase sub-
unit Aurora B kinase (AURKB), to prevent the formation of
aneuploid and polyploid cells [2]. However, when mitotic
errors cannot be corrected, they ultimately trigger mitotic
catastrophe (MC), a key mechanism that prevents the pro-
liferation and survival of mitotically aberrant cells through
either regulated cell death, such as apoptosis, or cellular
senescence [1, 3]. Failure of the MC process leads to per-
sistent genomic instability, a well-characterised hallmark of
cancer [4]. Therefore, MC is a critical mechanism to prevent
cells from becoming tumourigenic.
Caspase-2, the most evolutionarily conserved member of
the mammalian caspase family, was discovered over 2
decades ago [5]. Previous studies using knockout (KO)
mice have demonstrated that caspase-2 deficiency promotes
tumour development following replicative or oncogenic
stress [6–10]. Recent studies have demonstrated that
caspase-2 activation and its catalytic activity are critical
steps in MC signalling. Our previous studies demonstrated
that caspase-2-deficient cells acquire extensive aneuploidy
following replicative stress in culture [11], following
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prolonged mitotic arrest caused by inhibition of polo-like
kinase 1 (Plk1) [12] and in the bone marrow of aged
caspase-2 KO mice [13]. This was partly caused by
decreased Bid cleavage, reduced cell death, and clonogenic
survival of aberrant mitotic cells [12]. Importantly, cells
from mice harboring catalytic-dead caspase-2 (Casp2C320S)
also showed increased aneuploidy following prolonged
mitotic arrest [12], suggesting importance of the activation
and enzymatic activity of caspase-2 in apoptotic death of
aneuploid cells. Other studies have demonstrated that
caspase-2 activation following cytokinesis failure following
AURKB inhibition triggers cleavage of MDM2, leading to
p53 stabilisation and cell cycle arrest, as an alternative
mechanism to prevent aneuploidy and polyploidy [14, 15].
Although this evidence shows that caspase-2 activation and
its activity are required to prevent survival and proliferation
of cells with mitotic defects, the molecular mechanisms
have not been well defined.
Previous studies indicate that activation of caspase-2 can
be modulated by phosphorylation in different experimental
conditions [16–18]. Caspase-2 activation is inhibited by
phosphorylation at S157 by casein kinase-2 in TNF-alpha-
related apoptosis-inducing ligand (TRAIL)-mediated apop-
tosis in cultured cells [17], S308 (S340 in human) by Cdk1-
cyclin B1 during mitosis [16] and S135 (S164 in human) by
calmodulin-dependent protein kinase II (CaMKII) in
Xenopus oocytes under nutrient rich conditions [18]. S340
is localised in the linker region between the large (P19) and
small (P14) subunits, suggesting that phosphorylation at
these sites acts to prevent caspase-2 processing and acti-
vation [16]. Recently, phosphorylation at T180 of caspase-2
by mitogen-activated protein kinase (MAPK) is involved in
lipid metabolism [19]. However, it is not known whether
phosphorylation at these sites regulates caspase-2 activation
and its activity in response to aberrant and/or failed mitosis.
In this study, we identified a number of previously
unknown phosphorylation sites in caspase-2. Specifically,
we demonstrate AURKB phosphorylates caspase-2 at the
highly conserved S384 residue within the small subunit.
Furthermore, our data indicate an alternative MC regulatory
mechanism through AURKB-mediated inhibitory phos-
phorylation of caspase-2 and suggest that inhibition of
AURKB activity is required to trigger apoptosis or cell
cycle arrest following failed mitosis.
Results
Identification of phosphorylation sites in caspase-2
In this study, we mainly utilised U2OS cells as these cells
have been used in similar studies [12, 14], arrest effectively
in mitosis [20, 21] and undergo cell death following mitotic
exit upon treatment with mitotic drugs [22, 23]. Previous
studies have shown that phosphorylation can inhibit
caspase-2 activation or regulate its interaction with other
molecules under different physiological conditions [16–19].
Therefore, we set out to define all potential caspase-2
phosphorylation sites in viable cells in culture. To identify
phosphorylation sites in caspase-2, liquid chromatography-
tandem mass spectrometry (LC–MS/MS) experiments were
conducted using trypsin-digested GFP immunoprecipitates
from U2OS-CASP2−/− cells transiently expressing GFP-
tagged catalytically inactive mouse caspase-2-C320G.
(Fig. 1a and Supplementary Fig. S1). The annotated peptide
sequence demonstrates all of the peptide fragments used for
phosphorylation site identification. In total, we identified 11
phosphorylation sites in caspase-2 (Fig. 1b, c), including
previously characterised residues S157, S164, T180 and
S340 [16, 18, 19], and six novel sites S24, S80, T161, S220,
S346 and S384. Phosphorylation at T158 in human caspase-
2 has also been reported in the PHOSIDA database, but its
role is functionally undefined [24].
Next, multiple amino acid sequence alignment showed
that S80, S157, T158, T180 and S220 are conserved in
mammals, whereas S340 and S346 are also conserved in
Xenopus caspase-2. Interestingly, S164 and S384 are most
highly conserved, especially S384, which is remarkably
well conserved among the different species including
Drosophila apical caspase Dronc and C. elegans CED3
(Fig. 1d). It is important to note that Dronc and CED3
respectively are the only CARD containing caspases in flies
and nematodes and are functionally analogous to both
mammalian caspase-2 and caspase-9 [25, 26]. This finding
suggests that caspase-2 S384 residue might be functionally
important.
Phosphorylation regulates caspase-2 activation and
function
The first step in caspase-2 activation is homodimerisation
via its CARD, followed by autoprocessing, and ectopic
expression of caspase-2 triggers cell death [27–29]. To
functionally characterise the newly identified phosphoryla-
tion sites in caspase-2, we generated phospho-mimetic (Ser/
Glu) and phospho-deficient (Ser/Ala or Thr/Val) mutants
for each residue and then examined whether transient
expression of these mutants affected the processing and
activation of caspase-2, by assessing the cleavage of its
substrates Bid and MDM2 [14, 15, 30]. As expected, WT
caspase-2-GFP but not the C320G mutant cleaved MDM2,
generating a p60 cleavage fragment (60 kDa) (Fig. 2a).
While most of the phosphorylation mutants could cleave
MDM2 to some extent, MDM2 cleavage was completely
abolished by expression of the S384E caspase-2 mutant
(Fig. 2a). Similarly, we found that all the phosphorylation
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site mutants, except S384E, showed reduced levels or loss
of full-length Bid, indicating complete cleavage. The
C320G mutant did not induce cleavage of Bid as expected
(Fig. 2b). We also observed reduced autoprocessing of
S384E, to a similar extent as seen with C320G. This was
shown by higher levels of full-length caspase-2-GFP protein
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(74 kDa) and reduced levels of the 18 kDa subunit band
compared to WT caspase-2 or other phospho site mutants
(Fig. 2a, b). These results demonstrate that the caspase-2
phospho-mimetic S384E mutation affects its autoprocessing
and catalytic activity. Consistent with these findings, and
similar to the C320G mutant, the expression of S384E also
exhibited reduced ability to promote cell death compared to
WT or S384A in Casp2−/− immortalised mouse embryonic
fibroblasts (MEFs) (Supplementary Fig. S3a, b).
We next assessed the enzymatic activity of the various
caspase-2 phosphorylation mutant cell lysates using an
in vitro caspase activity assay with the selective fluorogenic
caspase-2 substrate, VDVAD-AFC [31, 32]. Several mutants
showed significantly reduced VDVADase cleavage activity
compared to WT caspase-2, including T180V, S220A,
S220E, S346A, S384A and S384E (Supplementary
Fig. S4a). Interestingly, only the S384E mutant showed a
complete absence of enzymatic activity, similar to C320G or
the vector control (Supplementary Fig. S4a), further
demonstrating that mutation of this site impairs caspase-2
processing and substrate cleavage (Fig. 2). As the S384A
mutation also showed reduced enzymatic activity in vitro,
we generated additional unphosphorylatable mutants,
including Ser-to-Gly (small amino acid) and Ser-to-Thr
(uncharged, polar amino acid like serine) mutations at this
site. We observed that, similar to S384A, both the S384G
and S384T mutants were still able to cleave MDM2 and
could also be processed in transfected cells (Supplementary
Fig. S4b). Together, these results indicate that phosphor-
ylation at S384 inhibits caspase-2 activation and activity in
cells and that several phosphorylation site mutations can
affect the enzymatic activity of caspase-2, but they do not
impair its substrate cleavage and cell death inducing activity.
Caspase-2-S384E does not disrupt dimerisation
As homodimerisation is sufficient for initial caspase-2
activation [27], we examined whether the S384E mutation
affected caspase-2 dimerisation using the bimolecular
fluorescence complementation (BiFC) assay, a visualizing
tool of protein–protein interaction [12, 33], with full-length
caspase-2-S384E and CASP2-C320A. We blocked mitosis
using the Plk1 inhibitor BI2536 (BI), which we have pre-
viously demonstrated to result in caspase-2 dimerisation
[12]. There were no differences in dimerisation of caspase-
2-S384E or CASP2-C320A between control (DMSO) and
BI treatment (Fig. 3a, b). Expression of GST recombinant
caspase-2-WT, C320G or S384E in E. coli showed that WT
GST-caspase-2 was cleaved to form an intermediate (~50
kDa) and fully processed large subunit (18 kDa), whereas
GST-caspase-2-S384E was not processed and behaved like
the recombinant C320G protein (Fig. 3c). This demon-
strates that caspase-2-S384E substitution prevents autopro-
cessing of caspase-2. Caspase assays using VDVAD-AMC
showed robust catalytic activity by WT caspase-2 but not by
both the C320G and S384E (Fig. 3d), which further con-
firmed that caspase-2-S384E mutant protein lacks catalytic
activity. Our data suggest that phosphorylation at S384 does
not prevent the initial caspase-2 dimerisation event, but
Fig. 1 Proteomic analysis identified six new phosphorylation sites
in caspase-2. a Schematic diagram of phosphorylation site analysis of
caspase-2. b Caspase-2 phosphorylation sites identified by LC–MS/MS.
The phosphorylated amino acid position, charge, mass error, peptide
location in caspase-2, phosphorylated S/T site position in caspase-2 and
localisation probability are indicated. Phosphorylated residues are indi-
cated in brackets. Spectra for the peptides in (b) can be found in Sup-
plementary Fig. S2. c Phosphorylation sites in caspase-2 identified by
mass spectrometry. Functionally reported sites are indicated in red. S
(Ser) or T (Thr) (in black) indicates positions of novel potential phos-
phorylation sites. NLS nuclear localisation signal. C320 catalytic Cys.
d Multiple amino acid sequence alignment showing conservation of
phosphorylation sites in caspase-2 from different species. Newly iden-
tified and known phosphorylation sites with high homology are shaded
in purple and grey, respectively.
Fig. 2 Caspase-2-S384E mutant does not cleave MDM2 or Bid.
a U2OS-CASP2−/− cells were transfected with 1 µg of GFP mock
vector, or GFP-tagged caspase-2 WT, C320G, or phosphorylation site
mutants as indicated. Cell lysates were subjected to immunoblotting
with the indicated antibodies. β-actin was used as loading control.
b U2OS-CASP2−/− cells were co-transfected with 1 µg of GFP mock
vector, or GFP-tagged caspase-2 WT, C320G, or phosphorylation site
mutants along with 500 ng of Bid-HA. Cell lysates were subjected to
immunoblotting with the indicated antibodies. β-actin was used as
loading control.
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inhibits autoproteolysis and downstream activation, and
therefore likely exerts a dominant negative function.
Caspase-2 S384 is a target of Aurora B kinase
We used computational tools and databases including
PHOSIDA, Scansite and KinasePhos 2.0 and identified
AURKB as a potential kinase for phosphorylation of S384
in caspase-2. The consensus phosphorylation motifs for
AURKB are (K/R)1-3-X-(S/T) or (K/R)-(R/K)-X0-2-(S/T),
where X indicates any amino acid [34, 35]. Such a sequence
is present around S384 in caspase-2 (Fig. 1d). We first
performed a GST-Casp2 pull-down assay to examine
whether AURKB directly binds to caspase-2 and found that
GST-Casp2 full-length (GST-Casp2-fl) coprecipitated with
AURKB (Fig. 4a). Furthermore, a small peptide fragment of
caspase-2 comprising the S384 residue (aa 363–423; GST-
Casp2363–423) also coprecipitated with AURKB (Fig. 4b).
Fig. 3 Caspase-2-S384E mutant can still homodimerise but lacks
enzymatic activity. a Representative confocal images showing
dimerisation of Casp2-S384E or CASP2-C320A by BiFC. U2OS-
CASP2−/− cells were transfected with Casp2-S384E or CASP2-C320A
BiFC constructs, respectively, together with pDsRED-Mito as trans-
fection reporter and treated with DMSO or 100 nM BI2536 (BI) for 24
h. All cells were also treated with z-VAD (20 µM), pan-caspase
inhibitor. DAPI (blue); pDsRED-Mito (red). Arrows indicate dimer-
ised caspase-2 (Green). Scale bar= 20 μm. b Quantitation of relative
BiFC-positive cells are indicated. *p < 0.05. c Immunoblot analysis
of recombinant GST-caspase-2-WT, C320G and S384E protein
expression and autoprocessing. ‘*’, truncated GST-caspase-2. d Cas-
pase activity of recombinant GST-caspase-2-WT, C320G and
S384E protein, was assessed by cleavage of VDVAD-AMC. GST
protein was used as a control. Data represented as mean ± SEM from
three independent experiments. **p < 0.01 compared to GST-caspase-
2-WT.
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To examine the interaction between caspase-2 and AURKB
in cells, we performed a coimmunoprecipitation (Co-IP)
experiment using U2OS-CASP2−/− cells stably expressing
GFP (sKO) or GFP-caspase-2-C320G (sC320G). AURKB
coimmunoprecipitated with caspase-2 predominantly in the
mitotic cell fraction but not in asynchronous or AURKB
inhibitor (ZM) treated cells (Fig. 4c). Next, we performed
an in vitro phosphorylation assay using AURKB with either
Fig. 4 Aurora B kinase phosphorylates caspase-2 at S384 in vitro.
a, b In vitro interaction between purified recombinant GST-Casp2-
C320G (GST-Casp2-fl) or GST-Casp2363–423-WT and His-AURKB
was determined by GST pull-down assay. Stain-free membrane shows
protein loading amount for GST or GST-Casp2. Antibodies used are
indicated. c U2OS-CASP2−/− cells stably expressing GFP (sKO) or
GFP-caspase-2-C320G (s320G) were used. GFP or GFP-caspase-2-
C320G were immunoprecipitated (IP) with GFP-Trap from the asyn-
chronous (Async), mitotic or ZM447439 (ZM)-treated cells
and subjected to immunoblotting with the indicated antibodies.
Phospho-histone H3 (pHis-H3) was used as mitosis marker. Stain-free
membrane was used as loading control. d GST-Casp2-fl WT, GST-
Casp2-fl S384A, GST-Casp2363–423 WT, GST-Casp2363–423 S384A or
GST was subjected to in vitro phosphorylation by incubation with
AURKB and [γ-32P]-ATP and analysed by autoradiography. IB with
GST antibody shows equal loading. MBP, myeloid basic protein was
used as positive control for AURKB phosphorylation.
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GST-Casp2-fl WT or the S384A mutant. The result demon-
strated that full-length caspase-2 is phosphorylated by
AURKB (Fig. 4d). Furthermore, in vitro phosphorylation
using GST-Casp2363–423 WT or S384A confirmed that S384
of caspase-2 is phosphorylated by AURKB (Fig. 4d). Nota-
bly, AURKB phosphorylation was almost completely abol-
ished in the GST-Casp2363–423 S384A fragment but was only
diminished in the GST-Casp2-fl S384A (Fig. 4d), suggesting
that AURKB might phosphorylate additional residues
besides S384. Interestingly, Aurora A kinase (AURKA) did
not phosphorylate S384 (Supplementary Fig. S5), indicating
that this residue is a specific site for AURKB. Together, these
data suggest that S384 of caspase-2 is target of AURKB and
is predominantly phosphorylated in mitosis.
Caspase-2-S384E expression results in increased
polyploidy and resistance to cell death following
mitotic stress
To further characterize the functional consequence of
phosphorylation at S384, we established a series of U2OS
cells stably expressing GFP (sWT) or U2OS-CASP2−/−
cells stably expressing GFP (sKO), GFP-tagged caspase-2-
C320G (sC320G) or S384E (sS384E clones #1 and #2)
(Supplementary Fig. S6). These cell lines were treated with
the AURKB inhibitor ZM447439 (ZM) [36] to induce
polyploidy and then cleavage of caspase-2 and its substrate
MDM2, was analysed by immunoblotting (IB) and DNA
content was measured by flow cytometry. Consistent with
previous reports [14, 15], sWT cells showed cleavage of
caspase-2 (p18 kDa), MDM2 and increased p53 and p21
accumulation in response to AURKB inhibition (Fig. 5a).
The sKO cells still showed increased p53 levels following
ZM treatment, albeit less than sWT cells, but p21 levels
were not increased and cleavage of MDM2 was absent,
which is consistent with previous findings (Fig. 5a) [14].
Interestingly, similar to sKO and sC320G, the two inde-
pendent sS384E cell lines also showed absence of MDM2
cleavage and p21 increase in response to ZM, while still
exhibiting induction of p53 (Fig. 5a). DNA content analysis
of sKO cells showed significantly increased polyploid
(>4N) cell accumulation compared to sWT cells (Fig. 5b, c),
which is consistent with previous reports [14, 15]. Simi-
larly, sC320G and sS384E cell lines also showed increased
polyploidy following ZM treatment (Fig. 5b, c).
We also used an alternative approach to induce poly-
ploidy by treating cells with blebbistatin to inhibit non-
muscle myosin II, which plays an essential role in the
constriction of the actomyosin contractile ring during
cytokinesis [37, 38]. Importantly, similar results were
observed when the U2OS stable cell lines were treated with
blebbistatin, although the accumulation of p53 reduced
(Fig. 6a), particularly when compared to treatment with the
AURKB inhibitor, AZD1152 [36] (Supplementary
Fig. S7a) in U2OS parental and CASP2−/− cells. Polyploidy
was also significantly increased in sKO, sC320G and
sS384E cell lines compared to the sWT although the
increase is not as robust as with AURKB inhibitor treatment
(Fig. 6b and Supplementary Fig. S7b).
We also treated U2OS stable cell lines with the Plk1
inhibitor, BI2536 (BI), which induces mitotic arrest, chro-
mosome missegregation, aneuploidy and caspase-2 depen-
dent apoptotic cell death [12]. Following treatment with BI,
the sKO, sC320G and sS384E cell lines were more resistant
to apoptosis than sWT cells (Fig. 7a). The sWT cells also
showed caspase-2 activation, cleavage of PARP, caspase-3
and Bid, demonstrating BI-induced cell death (Fig. 7b). As
previously reported, sKO and sC320G cells showed reduced
cleavage of PARP, Bid and caspase-3 [12] and this was also
observed in the sS384E cell lines (Fig. 7b). Taken together,
these experiments confirmed that phosphorylation of S384
inhibits caspase-2 activity and its cell death function.
We then examined whether re-expression of caspase-2
WT, S384A or S384E can rescue caspase-2-mediated MC
signalling, in two different cell lines, U2OS-CASP2−/− and
A549-CASP2−/− cells. Only the caspase-2 WT and S384A
expressing cells showed caspase-2 activation and complete
processing (p18) following ZM treatment, whereas C320G
and S384E did not (Supplementary Fig. S8a, b). Also,
MDM2 cleavage was observed in caspase-2 WT or S384A
expressing U2OS-CASP2−/− and A549-CASP2−/− cells, but
not in cells expressing C320G or S384E (Supplementary
Fig. S8a, b). Interestingly, more MDM2 cleavage was
observed in S384A expressing cells compared to the cells
expressing WT caspase-2. These data further indicate that
phosphorylation at S384 in caspase-2 is critical to regulate
caspase-2 activation and activity in MC.
Discussion
In the present study, we identified six new phosphorylation
sites in mouse caspase-2 by LC–MS/MS. We used the
catalytically inactive caspase-2-C320G mutant, because
unlike WT caspase-2, it is not associated with cytotoxicity
when expressed ectopically [27]. This allowed us to identify
new phosphorylation sites associated with full-length cas-
pase-2 zymogen. Of the six newly identified phosphoryla-
tion sites, we found that S384, which is highly conserved, is
critical for the regulation of caspase-2 activity and function.
Our studies utilising re-expression of caspase-2 mutants in
caspase-2 deficient cells demonstrated that the caspase-2-
S384E phospho-mimetic mutant prevents caspase-2 acti-
vation and its catalytic activity. Firstly, S384E caspase-2
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shows reduced autoprocessing of recombinant protein in
cells. While we observed some caspase-2 cleaved products
(p33 and p18) in S384E and C320G overexpressing cells,
recombinant protein did not show caspase-2 autoprocessing
or catalytic activity. These cleaved products were reduced
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transiently expressed in U2OS-CASP2−/−/CASP3−/− cells
(Supplementary Fig, S9) indicating the cleavage is likely
caused by caspase-3 [39] or other cellular proteases. Sec-
ondly, S384E was unable to cleave the known caspase-2
substrates, MDM2 and Bid. Thirdly, caspase-2-S384E can
still homodimerise but is catalytically inactive. Lastly,
expression of the caspase-2-S384E shows predominantly
nuclear localisation, similar to the C320G mutant, which
may also impede activation by other caspases in the cytosol.
Overall our results suggest that while S384E does not affect
dimerisation, the first step of caspase-2 activation, it pre-
vents autoproteolytic processing, cytosolic localisation and
complete caspase-2 activation. This may be in part caused
by steric hindrance on the substrate binding site. These data
suggest that S384E caspase-2 likely acts as a dominant
negative protein.
Caspase-2 is the only member of the caspase family that
preferentially recognises a pentapeptide, such as VDVAD
or ADVAD, as substrates over a tetrapeptide sequence
[31, 32, 40]. T380 and Y420 are key residues that have been
shown to be critical for binding the P5 residue [41]. These
residues form hydrogen bonds with P5 Val in VDVAD or
Ala in ADVAD pentapeptide substrates [41]. Also, W385
forms a hydrogen bond with P4 Asp. Interestingly, S384
localises next to W385 and close to T380 although it may
not directly interact with the substrate [41]. This suggests
that phosphorylation at S384 may cause an interference
with substrate binding (Fig. 8a, b) preventing the catalytic
activity of caspase-2.
We examined four different substitution mutants of S384
and found that only the S384E phospho-mimetic mutant
was enzymatically inactive. Although various other amino
acid substitutions on S384 may affect cleavage ability of
caspase-2, we have shown here that the region directly
surrounding S384 of caspase-2 can bind to AURKB in vitro
and in vivo (Fig. 4a–c), and S384 is phosphorylated by
AURKB (Fig. 4d). In addition, expression of the phospho-
deficient S384A mutant in caspase-2 deficient cells, can
rescue the cleavage of MDM2 following aberrant mitosis.
However, phosphorylation of S384 is unable to rescue MC
signalling (as demonstrated by expression of S384E)
(Supplementary Fig. S8). These findings, demonstrate that
phosphorylation of S384 by AURKB is critical to prevent
caspase-2 activation and activity.
Multiple kinases are responsible for phosphorylation of
caspases [42]. Our study identified AURKB as an important
additional kinase that phosphorylates caspase-2 at S384. We
also examined other kinases (including CaMKII, PKA,
PAK1, Cdk1, Plk1 and MAPK) but none of them phos-
phorylated the S384 site in caspase-2 (data not shown).
Analysis with the GPS 5.0 software (http://gps.biocuckoo.
cn) predicted five possible additional AURKB phosphor-
ylation sites in caspase-2, of which only two, S24 and S157,
were identified by MS in this study. We tested S24
phospho-mutants but found this residue was not essential
for caspase-2 function. While S157 may be an AURKB
target site, our data indicate that phosphorylation on S384 is
sufficient to prevent activation and catalytic activity of
caspase-2. AURKB has various critical functions in mitosis,
including chromatin condensation, kinetochore-microtubule
error correction and cytokinesis [43]. Therefore, our find-
ings suggest that AURKB phosphorylation maintains
caspase-2 in an inactive state throughout cell division.
Notably, caspase-2 is also regulated by Cdk1-mediated
inhibitory phosphorylation at S340 during mitosis [16].
However, while Cdk1 activity is inhibited following
degradation of its cyclin B partner at anaphase onset,
AURKB remains active until late cytokinesis [44]. Impor-
tantly, AURKB, along with its CPC partners, can delay the
final separation (i.e. abscission) of the two daughter cells in
the presence of lagging chromatin at the cleavage site to
prevent aneuploidy and polyploidy [45]. Therefore, it
appears that caspase-2 is under tight regulation by multiple
mitotic kinases to prevent any accidental cell death during
cell division. Our studies using the S384E mutant expres-
sion in U2OS cells and recombinant S384E caspase-2
protein in vitro demonstrate that phosphorylation at S384
prevents caspase-2 catalytic activity and function. There-
fore, the inhibition of S384 phosphorylation by specific
targeting of this site, or by targeting AURKB may be an
effective mechanism of activating caspase-2 in cycling
cells. However, it would be important to decipher whether
S384 dephosphorylation could effectively activate caspase-
2 during other cell cycle stages or in senescent cells.
Interestingly, blebbistatin, which does not inhibit AURKB,
also causes cytokinesis failure and caspase-2 activation
indicating potentially differential regulation of caspase-2 at
different mitotic stages. Importantly, the caspase-2-S384E
was also not activated following blebbistatin treatment,
suggesting an important role for AURKB-mediated phos-
phorylation in regulating caspase-2 activation during gen-
eral cytokinesis failure. It has been shown that PP1 can
Fig. 5 Caspase-2-S384E expressing cells fail to cleave MDM2 and
show increased polyploidy following AURKB inhibition. GFP-
expressing U2OS (sWT) and U2OS-CASP2−/− expressing GFP (sKO),
GFP-caspase-2-C320G (sC320G) or GFP-caspase-2-S384E (sS384 #1
and #2) were treated with DMSO or 2 µM ZM447439 (ZM) for 48 h
and subjected to immunoblot and DNA content analysis. a Repre-
sentative immunoblots (from three independent experiments) of cell
lysates from treated stable cell lines. Antibodies used for immuno-
blotting are as indicated. β-actin was used as loading control. b
Representative flow cytometric profiles of the DNA content in cells
following ZM treatment. The percentage represents polyploid cells
(>4N), which was calculated using FACS Express 6 cell cycle analysis
module. c Graph comparing percentage of cells with polyploid (>4N)
DNA content following ZM treatment. Mean ± SEM; n= 3. *p < 0.05;
**p < 0.01 compared to sWT + ZM.
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dephosphorylate caspase-2 S340 residue, leading to
caspase-2 activation and cell death [16, 46]. Therefore,
identification of the phosphatase(s) of S384 that can trigger
caspase-2 activation may provide an important mechanism
to eliminate polyploid cells.
We propose that during normal mitosis caspase-2 is
maintained in an inactive state by both Cdk1 and AURKB-
mediated phosphorylation until anaphase onset and then
only by AURKB-mediated phosphorylation at S384 until
abscission. If MC is triggered before anaphase, by failure of
chromosome alignment for example, inhibition/reduction of
Cdk1 and AURKB, and dephosphorylation at both S340
and S384 would activate caspase-2 to promote cell death. If
instead there are irrecoverable problems specifically during
cytokinesis, such as persistent lagging chromatin, then the
inactivation/reduction of AURKB would enable depho-
sphorylation at S384 to trigger caspase-2 activation and
apoptosis (Fig. 8c). Reduced AURKB levels have pre-
viously been shown to cause MC as well as premature
Fig. 7 Caspase-2-S384E expressing cells are resistant to aberrant
mitosis-mediated cell death. GFP-expressing U2OS (sWT) and
U2OS-CASP2−/− expressing GFP (sKO), GFP-caspase-2-C320G
(sC320G) or GFP-caspase-2-S384E (sS384 #1 and #2), were treated
with DMSO or 100 nM BI2536 (BI) for 48 h and subjected to
immunoblot and MTS assay. a Plot showing percentage of viable cells
following BI treatment. Mean ± SEM; n= 3. *p < 0.05; **p <
0.01 compared to sWT. b Representative immunoblots (from three
independent experiments) of cell lysates from treated stable cell lines.
Antibodies used for immunoblotting are as indicated. β-actin was used
as loading control.
Fig. 6 Caspase-2-S384E expressing cells fail to cleave MDM2 and
show increased polyploidy following cytokinesis block with bleb-
bistatin. GFP-expressing U2OS (sWT) and U2OS-CASP2−/−
expressing GFP (sKO), GFP-caspase-2-C320G (sC320G) or GFP-
caspase-2-S384E (sS384 #1 and #2), were treated with DMSO or 50
µM blebbistatin (Bleb) for 48 h and subjected to immunoblot and DNA
content analysis. a Representative immunoblots (from five indepen-
dent experiments) of cell lysates from treated stable cell lines. Anti-
bodies used for immunoblotting are as indicated. β-actin was used as
loading control. b Graph comparing percentage of cells with polyploid
(>4N) DNA content following Bleb treatment. The percentage of
polyploid cells (>4N) was calculated using FACS Express 6 cell cycle
analysis module. Mean ± SEM; n= 5. *p < 0.05; **p < 0.01 compared
to sWT+ Bleb.
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Fig. 8 Phosphorylation at S384 affects the conformation of the
substrate binding pocket. a The crystal structure of human active
caspase-2/VDVAD (PDB ID: 3R6G) [41] complex. Crystalised
caspase-2 is composed of two p19/p12 heterodimers. b Magnified
view showing position of S384 and surrounding amino acid residues
important for substrate binding. T380 and Y420 and W385 are shown
in magenta and interact with P5 and P4 residues [41]. S384 and C320
are shown in orange and red, respectively. c Schematic showing reg-
ulation of caspase-2 by AURKB-mediated phosphorylation in mitosis.
During normal mitosis, S384 of caspase-2 is phosphorylated by
AURKB, maintaining caspase-2 in inactive state. In response to
aberrant mitosis, such as cytokinesis failure and chromosome mis-
segregation, reduced AURKB activity enables S384 depho-
sphorylation by protein phosphatase(s) (PP). This leads to caspase-2
activation that can result in two outcomes: either cleavage of MDM2,
which leads to p53 stabilisation and cell cycle arrest, or cleavage of
Bid, which leads to outer mitochondrial membrane permeabilization
(MOMP), caspase-3 activation and apoptotic cell death. Increased
AURKB levels (and reduced caspase-2 activation) are associated with
chromosome instability. Therefore, these caspase-2 activation path-
ways limit cells becoming aneuploid or polyploid, preventing chro-
mosome instability. Dashed lines indicate unknown mechanisms.
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mitotic exit and we now demonstrate that this directly
causes caspase-2 activation as a mechanism to prevent
survival of cells that slip through mitosis and become
polyploid.
Overexpression and enhanced kinase activity of AURKB
in various tumour types are well documented and associated
with therapy resistance and low survival rate in various
cancers. Therefore, AURKB is considered as a potential
therapeutic target in cancer [47]. Together with our data
presented here, this suggests that in tumour cells, AURKB
may act to maintain caspase-2 in a phosphorylated inactive
state, thereby preventing apoptotic cell death that con-
tributes to therapy resistance. We therefore propose that the
phosphorylation state of caspase-2 may predict apoptosis
sensitivity and treatment response in cancer.
Cytokinesis failure induced by AURKB inhibition has
previously been shown to induce caspase-2 activation,
MDM2 cleavage and accumulation of p53 and cell cycle
arrest in both U2OS and A549 cells [14, 15]. We have
also previously observed increased polyploidy in U2OS-
CASP2−/− cells, as a consequence of the accumulation of
uncleaved, full-length MDM2, but still associated with
increased p53 levels [14]. This suggested the presence of
an MDM2-independent p53 response following aberrant
mitosis, in caspase-2 deficient cells [14]. In this study, we
now demonstrate that, similar to CASP2−/− cells or
C320G expression, cells stably expressing the caspase-2-
S384E mutant acquire increased polyploidy associated
with lack of MDM2 cleavage. Importantly, we have
also observed this, using a different cytokinesis inhibitor,
blebbistatin [37], that induces polyploidy. These data
confirm that our results are a consequence of general
cytokinesis failure and phosphorylation of caspase-2 at
S384 can prevent the canonical MC response and
exacerbate polyploidy.
We have previously demonstrated that caspase-2 acti-
vation and its catalytic activity are required for Bid-
mediated apoptotic cell death of aneuploid cells [12]. Our
findings now demonstrate that the caspase-2-S384E cell line
does not show Bid cleavage and is more resistant to
apoptosis caused by Plk1 inhibition. This further suggests
that as well as causing accumulation of MDM2, and dam-
pening p53-mediated cell cycle arrest, the S384E mutant
prevents caspase-2-mediated apoptosis.
Taken together, our data suggest that AURKB-
mediated phosphorylation at S384 of caspase-2 is a cri-
tical mechanism that regulates its activation and cellular
functions. As activation of caspase-2 is required following
MC to prevent survival of polyploid cells following failed
mitosis and failure to repair damaged DNA [1, 3], it will
be important to examine in future, whether phosphoryla-




The following antibodies were used: anti-caspase-2 (clone
11B4; produced in-house [48] and available from Merck
#MAB3507); anti-GFP (600-101-215, Rockland, Limerick,
PA, USA); anti-MDM2 (OP46, EMD Millipore, Billerica,
MA, USA); anti-p53 (sc-126, Santa Cruz Biotechnology,
Dallas, TX, USA)); anti-p21 (5567430, BD Bioscience,
Franklin Lakes, NJ, USA); anti-PARP (9542, Cell Signal-
ling Technology, Beverly, MA, USA); anti-Bid (2002, Cell
Signalling Technology); anti-cleaved caspase-3 (9664, Cell
Signalling Technology); anti-HA (H6908, Sigma-Aldrich,
St. Louis, MO, USA); anti-GST (G7781, Sigma-Aldrich);
anti-Phospho-Histone H3 (9701, Cell Signalling Technol-
ogy); anti-His (ab18184, Abcam, Cambridge, MA, USA)
and anti-β-actin (A1978, Sigma-Aldrich).
Cell culture and transfection
U2OS (ATCC, Manassas, VA, USA), U2OS-CASP2−/−,
U2OS-CASP2−/−/CASP3−/−, A549, A549-CASP2−/− and
stable cell lines were maintained in Dulbecco’s Modified
Eagles Medium (DMEM, Sigma-Aldrich) supplemented
with 10% foetal bovine serum (JRH Biosciences, Lenexa,
KS, USA), 0.2 mM L-glutamine (Sigma-Aldrich), 15 mM
HEPES (Sigma-Aldrich) and 100 µM penicillin/streptomy-
cin (Sigma-Aldrich) in a humidified incubator at 37 °C with
10% CO2. A549 and A549-CASP2
−/− cell lines were pro-
vided by Prof. Villunger (Medical University of Innsbruck,
Austria). Where indicated, cells were treated with 100 nM
BI2536 (Axon Medchem, Netherlands), 2 µM ZM447439
(Sigma-Aldrich), 400 nM AZD1152-HQPA (Sigma-
Aldrich), or 50 µM blebbistatin (Selleck Chemicals, Hous-
ton, TX, USA) for 24 or 48 h. MEFs were maintained in
DMEM (Sigma-Aldrich) supplemented with 0.2 mM
L-glutamine (Sigma-Aldrich), 15 mM HEPES (Sigma-
Aldrich), 10% foetal bovine serum (JRH Biosciences) and
50 µM β-mercaptoethanol (Sigma-Aldrich), non-essential
amino acid mix (Sigma-Aldrich), 100 µM penicillin/ strep-
tomycin (Sigma-Aldrich). Cells were cultured in a humi-
dified incubator at 37 °C with 10% CO2. Transfection of
plasmid DNA was performed using Lipofectamine 3000
(Life Technologies, Carlsbad, CA, USA) according to the
manufacturer’s instructions. All cell lines were tested for
mycoplasma contamination.
Cloning of caspase-2 phospho site mutants and
other constructs
All phosphorylation site mutants were generated by Quik-
Change site-directed mutagenesis of pEGFP-mouse caspase-2
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WT [49] or pcDNA-DEST47-mouse caspase-2-WT (for
T161A) as PCR template. All primer sequences are outlined
in Supplementary Table S1. To produce BiFC-caspase-2-
S384E constructs, the caspase-2-S384E was amplified from
the pEGFP-caspase-2-S384E using the following PCR pri-
mers: VN-caspase-2-S384E (forward: 5′-AAAGATCTCGC
GGCGCCGAGCGGGAG-3′ and reverse: 5′-AATCTAGA
CGTGGGTGGGTAGCCTGG-3′ with added BglII and XbaI
site); VC-caspase-2-S384E (forward: 5′-AAAGATCTCCGC
GGCGCCGAGCGGGAG-3′ and reverse: 5′-AACTCGAG
TCGTGGGTGGGTAGCCTGG-3′ with added BglII and
XhoI site). The amplified fragments were cut with BglII/XbaI
or BglII/XhoI and subsequently subcloned in-frame into
pBiFC-VN173 and pBiFC-VC155 (gifts from Lisa Bouchier-
Hayes, Baylor College of Medicine, Houston, TX, USA),
respectively. For bacterial expression, pGEX4T3-caspase-2-
WT [27] was used as a template for PCR-based mutagenesis
to introduce the S384E, S384A or C320G mutations, fol-
lowed by insertion into the BamHI and XhoI sites of
pGEX4T3. To obtain the small fragment of caspase-2 con-
taining S384 (Casp2363–423-WT or -S384A), the correspond-
ing fragments (aa 363–423) were amplified from the
pGEX4T3-caspase-2-WT or -S384A using the following
PCR primers: (forward: 5′-AAAGGATCCGACATGAT
ATGTGGCTATGCTTG-3′ and reverse: 5′-AAACTCGAG
TTAGCCAGGGGCATAG CCTTC-3′) and subcloned into
pGEX-4T-3 using BamHI and XhoI sites. To obtain human
AURKB expression plasmid construct, full-length AURKB
was amplified from cDNA made from U2OS cells using the
following PCR primers: (forward: 5′-AAACATATGG
CCCAGAAGGAGAACTCC-3′ and reverse: 5′-AAACTCG
AG GGCGACAGATTGAAGGGC-3′) and subcloned into
pET-32a vector plasmid via NdeI and XhoI sites. Each con-
struct was confirmed by DNA restriction enzyme digestion
and DNA sequencing. All DNA restriction enzymes were
purchased from NEB (Ipswich, MA, USA).
Expression and purification of recombinant proteins
The plasmids pGEX4T3-caspase-2-WT, -S384E or -S384A,
pGEX4T3-Casp2363–423 (WT or S384A) or pET-32a-
AURKB were transformed into E. coli BL21(DE3)pLysS
(Promega, Madison, WI, USA). Single colonies were
inoculated into 50 mL LB with 100 µg/mL ampicillin and
cultured overnight at 37 °C with shaking at 180–200 rpm.
The next day, 10 mL overnight culture was diluted
into 400 mL LB with ampicillin (100 µg/mL) and cultured
at 30 °C. To induce recombinant proteins isopropyl-β-D-
thiogalactoside (IPTG, Sigma-Aldrich) was added (0.1 mM)
when OD600 was between 0.4 and 0.6 and the culture was
incubated for 24 h at 16 °C. Bacterial cells were harvested
by centrifugation at 5000 rpm for 10 min at 4 °C. For GST-
tagged recombinant protein purification, the pellet was
resuspended in 20 mL of cold lysis buffer (25 mM HEPES,
10% sucrose, 0.1% CHAPS, 1 mM EDTA, 10 mM DTT,
pH 7.4) with protease inhibitor (Sigma-Aldrich), followed
by sonication (10 × 20-s pulses). Triton X-100 (Sigma-
Aldrich) was then added to a final concentration 0.1% and
incubated for 1 h at 4 °C with rocking, followed by cen-
trifugation at 15 000 rpm for 30 min at 4 °C. Supernatant
was transferred to a new 50 mL falcon tube and 250 µL bed
volume of PBS-washed glutathione Sepharose beads (GE
Healthcare Australia) was added to the lysate, followed by
overnight incubation at 4 °C with rocking. Supernatant
containing beads were transferred to a column in a 4 °C cold
room and flow through was collected. Beads were then
washed four times with 10 mL PBST (PBS, 0.1% Triton X-
100). GST-tagged recombinant protein was eluted in 10
bead volumes of elution buffer (50 mM Tris, 10 mM
reduced glutathione, pH 8.0) in 10 fractions. For AURKB
purification, bacterial pellet was resuspended in 20 mL of
cold His-lysis buffer (50 mM NaH2PO4, 300 mM NaCl,
10 mM imidazole, pH 8.0) with protease inhibitor (Sigma-
Aldrich), followed by sonication (10 × 20-second pulses)
and centrifugation at 15 000 rpm for 30 min at 4 °C. The
supernatant was transferred to a new 50 mL falcon tube and
250 µL bed volume of Ni-Sepharose (GE Healthcare,
Waukesha, WI, USA) was added to the lysate, followed by
overnight incubation at 4 °C with rocking. Lysate contain-
ing beads were transferred to a column in the cold room and
flow-through was collected. Beads were washed four times
with 10 mL of wash buffer (50 mM NaH2PO4, 300 mM
NaCl, 20 mM imidazole, pH 8.0). His-AURKB was eluted
in 10 bead volumes of elution buffer (50 mM NaH2PO4,
300 mM NaCl, 250 mM imidazole, pH 8.0) and collected in
10 fractions. Purified proteins were checked by SDS-PAGE
analysis. Pooled eluates were dialysed against 50 mM Tris-
HCl, pH 7.5. Protein concentration was quantitated with
BCA Protein Assay (Thermo Fisher Scientific, Rockford,
IL, USA) and stored in aliquots at −80 °C until used.
Purification of caspase-2-C320G-GFP
U2OS-CASP2−/− cells were seeded into 16 × 100 mm
dishes at a total density of 1.5 × 106 cells/dish. Cells were
treated with 20 µM Z-VAD for 2 h and then transfected with
6 µg pEGFP-caspase-2-C320G for 48 h. The cells were
harvested and lysed in RIPA buffer [25 mM Tris-HCl pH
7.4, 150 mM NaCl, 1% nonyl-phenoxylpolyethoxylethanol
(NP-40), 1% sodium deoxycholate, 0.1% sodium dodecyl
sulfate (SDS)] supplemented with 1X Halt Protease and
Phosphatase Inhibitor Cocktail, EDTA (Thermo Fisher
Scientific), and 10 µM N-ethylmaleimide (Sigma-Aldrich).
Lysed cells were sonicated, and lysates cleared by cen-
trifugation at 13 200 rpm (4 °C). GFP-Trap (ChromoTek,
Germany) was used to purify caspase-2-C320G-GFP,
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according to the manufacturer’s instruction. Briefly, 150 µL
GFP-Trap_MA bead suspension was equilibrated by
washing with RIPA buffer three times. Cell lysates were
added to the GFP-Trap_MA beads and incubated at 4 °C
overnight with gentle rocking. The beads were then sepa-
rated magnetically until the supernatant was clear. The
supernatant was collected as ‘flow-through’ sample for
SDS-PAGE and western blot analysis. The beads were
resuspended in 1 mL ice-cold wash buffer (10 mM Tris-
HCl, 150 mM NaCl, 0.5 mM EDTA, pH 7.5), briefly spun
and magnetically separated. The supernatant was removed,
and washing was repeated four more times with high salt
wash buffer (10 mM Tris-HCl, 500 mM NaCl, 0.5 mM
EDTA, pH 7.5). Bound GFP-caspase-2-C320G was eluted
by adding 50 µL elution buffer (0.2 M glycine pH 2.5),
followed by incubation for 2 min and magnetic separation.
The supernatant was transferred to a new tube and 5 µL of 1
M Tris (pH 10.4) was added for neutralisation. Elution was
repeated three times. A sample of each fraction (10 µL) was
subjected to SDS-PAGE analysis and Coomassie blue
staining (Supplementary Fig. S1). ‘Elution 1’ was utilised
for proteomic analysis.
Mass spectrometry and data analysis
Protein samples were resuspended in 6M urea, 100 mM
DTT and 100 mM Tris-HCl (pH 7.0) and subjected to
protein digestion using FASP (filter aided sample prepara-
tion) [50]. Peptides were collected and acidified with formic
acid (FA) to a 1% final concentration. Solvent was removed
in a CentriVap concentrator (Labconco, Kansas, MO, USA)
and peptides were resuspended in Milli-Q water containing
1% acetonitrile (ACN) and 1% FA. Samples were analyzed
by nanoflow LC–MS/MS on a nanoAcquity system
(Waters, Milford, MA, USA) coupled to a Q-Exactive Mass
Spectrometer (Thermo Fisher Scientific) through a nanoe-
lectrospray ion source (Thermo Fisher Scientific). Peptide
mixtures were directly loaded onto a 250 mm column with
75 µm inner diameter (nanoAcquity UPLC 1.7 µm BEH130
C18) on a 120 min linear gradient from 1 to 35% buffer B
(A: 99.9% Milli-Q water, 0.1% FA; B: 99.9% ACN, 0.1%
FA) at a 400 nL/min constant flow rate. The Q-Exactive was
operated in a data-dependent mode, switching automatically
between one full-scan and subsequent MS/MS scans of the
ten most abundant peaks. The instrument was controlled
using Exactive series version 2.6 and Xcalibur 3.0. Full-
scans (m/z 350–1850) were acquired with a resolution of
70 000 at 200m/z. The ten most intense ions were
sequentially isolated with a target value of 10 000 ions and
an isolation width of 3m/z and fragmented using HCD with
normalized collision energy of 27 and stepped collision
energy of 15%. Maximum ion accumulation times were set
to 50 ms for full MS scan and 200 ms for MS/MS. Underfill
ratio was set to 2% and dynamic exclusion was enabled and
set to 60 s.
The raw files were analysed using the MaxQuant [51, 52]
software (version 1.5.8.3). The database search was per-
formed using mouse protein sequences obtained from
Uniprot including isoforms with strict trypsin specificity
allowing up to two missed cleavages. The minimum
required peptide length was set to seven amino acids.
Carbamidomethylation of cysteine was set as a fixed mod-
ification while N-acetylation of proteins N-termini, oxida-
tion of methionine, phosphorylation of S/T/Y and GlyGly
on lysine were set as variable modifications. During the
MaxQuant main search, precursor ion mass error tolerance
was set to 4.5 ppm and fragment ions were allowed a mass
deviation of 20 ppm. PSM and protein identifications were
filtered using a target-decoy approach at a false discovery
rate of 1%.
Protein pull-down assays
To examine the direct interaction between caspase-2 and
AURKB, GST pull-down assay was carried out. GST, GST-
Casp2-C320G or GST-Casp2363–423-WT (1 µg) was incu-
bated with 500 ng His-AURKB in 300 µL incubation buffer
(50 mM Tris-HCl, 10 mM MgCl2, 0.1 mM EDTA, 0.01%
Brij 35, pH 7.5) for 2 h with rotation, at room temperature.
This was followed by addition of 10 µL glutathione-agarose
beads (GE Healthcare) and further incubation for 1 h with
rotation at room temperature. After four washes with
incubation buffer, beads were heated in 2x Laemmli buffer
for 5 min at 95 °C. Samples and 10% inputs were then
subjected to SDS-PAGE and IB.
To examine the interaction between caspase-2 and
AURKB in cells, U2OS-CASP2−/− cells stably expressing
GFP (sKO) or GFP-Casp2-C320G (sC320G) were used. For
mitotic cells, sC320G cells were synchronized in G1/S by
treatment with 2 mM thymidine (Sigma-Aldrich) for 24 h.
After washing with PBS, the cells were released into com-
plete media for 3 h, followed by treatment with 100 ng/mL
nocodazole (Sigma-Aldrich) for 14 h. Mitotic cells were
collected by gentle shaking of the culture flasks. For AURKB
inhibition, sC320G cells were treated with AURKB inhibitor,
ZM447439 (ZM, 2 µM) for 24 h. The cells were lysed in NP-
40 lysis buffer (150mM NaCl, 1% NP-40, 50mM Tris-HCl,
pH 8.0) containing 1X Halt Protease and Phosphatase Inhi-
bitor Cocktail, EDTA (Thermo Fisher Scientific). The cell
lysates were then incubated with GFP-Trap for 2 h at 4 °C
with gentle rocking, followed by four washes in lysis buffer.
Bound GFP or GFP-caspase-2-C320G was eluted by adding
25 µL elution buffer (0.2M glycine, pH 2.5) as described
above. The pooled elutes were neutralised by adding 5 µL of
1M Tris (pH 10.4) and subjected to IB. Forty micrograms of
the cell lysates were used as input.
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Caspase-2 dimerisation assay
BiFC analysis for caspase-2 activation was performed as
described previously with minor modifications [53]. Briefly,
U2OS-CASP2−/− cells were seeded onto 13 mm glass
coverslips (Thermo Fisher Scientific) and incubated over-
night at 37 °C in a 10% CO2 incubator. The next day, the
medium was replaced with complete culture medium con-
taining 20 µM Z-VAD-FMK (Sigma-Aldrich) 2 h prior to
transfection. The cells were then co-transfected with 150 ng
of the pBiFC-HA-Casp2(S384E)-VC155 and pBiFC-HA-
Casp2(S384E)-VN173 (mouse caspase-2) for BiFC and 10
ng of pDsRed-Mito (Clontech, Takara Bio USA, Mountain
View, CA, USA) as a transfection reporter plasmid, using
Fugene HD reagent (Promega). pBiFC-HA-CASP2
(C320A)-VC155 and pBiFC-HA-CASP2 (C320A)-VN173
(human caspase-2) were used as system control [12]. After
incubation for 2 h, DMSO (control) or 100 nM BI2536
(Sigma-Aldrich) was added to the medium and cells were
incubated a further 24 h at 37 °C in a 10% CO2 incubator.
Cells were then fixed with 4% paraformaldehyde (Sigma-
Aldrich) in PBS and BiFC imaged by confocal microscopy
using a Leica TCS SP8 (Leica, Wetzlar, Germany). At least
100 cells were counted in five different areas in two inde-
pendent experiments to quantify BiFC-positive cells.
Caspase activity assay
Caspase activity assay using VDVAD-AFC was carried out
as previously described [54]. The protein concentration of
cell lysates were quantified by BCA Protein Assay (Thermo
Fisher Scientific) according to the manufacturer’s instruc-
tions and 50 µg of cell lysate was mixed with caspase-2
activity buffer (0.1 M MES [2-(N-morpholino) ethane-
sulfonic acid], 10% sucrose, 0.1% CHAPS, 0.5 mM EDTA,
pH 6.5) to a total volume of 50 µL. VDVAD-AFC (100 µM,
Sigma-Aldrich)) diluted in 50 µL of caspase-2 activity
buffer was added to each sample to give a final volume of
100 µL per well. Fluorescence was measured in 10 min
intervals for 170 min at 37 °C, with excitation= 400 nm,
emission= 505 nm, to quantitate caspase-2 activity. For
GST recombinant proteins, 20 µL of crude E. coli extract
was used.
Generation of KO cell lines
U2OS-Caspase-2 KO (U2OS-CASP2−/−) cell line was
generated using CRISPR/Cas9 technology as described
previously [55]. pSpCas9(BB)-2A-Puro (PX459) was a gift
from Feng Zhang (Addgene plasmid #48139; http://n2t.
net/addgene:48139; RRID:Addgene_48139) [55]. The
sgRNA oligos (sense: 5′-caccgaccaaaaatgttcttcatcc-3′; anti-
sense: 5′-aaacggatgaagaacatttttggtc-3′) were annealed,
phosphorylated by T4 PNK (NEB) and inserted into BbsI
(NEB) site of pSpCas9(BB)-2A-Puro (PX459) vector plas-
mid. To establish the KO cell line, 2 × 105 U2OS cells were
transfected with 2 µg of sgRNA and Cas9 expressing plasmid
using Fugene HD reagent (Promega) according to the man-
ufacturer’s instruction. pSpCas9(BB)-2A-GFP and pSpCas9
(BB)-2A-Puro (PX459) were also transfected as a negative
control and positive control, respectively, for puromycin
treatment. The cells were treated with 1 µg/mL puromycin for
2 days until all negative control cells had died. The surviving
cells were harvested and re-seeded into three 10 cm dishes at
1 × 103 cells/dish for isolating single colonies. To screen
candidate single clones, the sgRNA-targeted area was
amplified by PCR (forward: 5′-tggtggaagccaactgttgaaacc-3′;
reverse: 5′- tctcagaaaggaaggcaaagacacg-3′) and the PCR
products were analysed by heteroduplex analysis in PAGE
gel as described previously [56] and DNA sequencing. DNA
sequencing results were used for insertion and deletion ana-
lysis in the targeted gene area by TIDE software (http://tide.
nki.nl). Loss of caspase-2 expression in the candidate clones
was validated by western blot.
The U2OS-CASP2−/−/CASP3−/− cell line was generated
using one of the U2OS-CASP2−/− clones, as above. The
sgRNA oligos (sense: 5′-caccgattatacataaacccatctc-3′; anti-
sense: 5′-aaacgagatgggtttatgtataatc-3′) used for cloning into
pSpCas9(BB)-2A-Puro (PX459) vector plasmid. The
sgRNA-targeted area was amplified by PCR (forward: 5′-
gcctcacgtcaggtcatttt-3′; reverse: 5′-tgtaggtcctgcccaatctc-3′)
for genetic analyses. Western blot was performed to validate
loss of caspase-3 expression.
Immunofluorescence microscopy
U2OS cells stably expressing GFP (sWT) and U2OS-
CASP2−/− cells stably expressing GFP (sKO), GFP-Casp2-
C320G (sC320G) or GFP-Casp2-S384E (sS384E) were
generated using pEGFP mock, pEGFP-Casp2-C320G or
pEGFP-Casp2-S384E plasmids, respectively. For immuno-
fluorescence microscopy, cells were grown on coverslips
overnight and fixed in 4% paraformaldehyde in PBS for 10
min at room temperature. The fixed cells were washed in
TBS, permeabilized and blocked with blocking solution
(3% BSA, 0.1% Triton X-100 in TBS) for 1 h at RT.
Samples were incubated overnight with goat anti-GFP
antibody at 1:500 dilution in blocking solution. After three
washes in TBS/0.1% Triton X-100, coverslips were incu-
bated for 60 min with anti-goat IgG-Alexa568 (Molecular
Probes, Thermo Fisher Scientific) diluted in blocking
solution. Samples were washed another three times (as
above) and coverslips were mounted onto glass slides with
mounting medium containing DAPI (Life Technologies).
Images were taken with a Zeiss LSM-800 confocal micro-
scope (Zeiss, Germany).
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Immunoblotting
Protein samples were denatured for 5 min at 95 °C and run
on Mini or Midi TGX Stain-Free Precast Gels (Bio-Rad,
Hercules, CA, USA) at 110 V for 60 min (mini gels) or at
140 V for 60 min (midi gels) in SDS-PAGE running buffer
(250 mM Tris, 192 mM glycine, 0.06% SDS). The proteins
were transferred onto PVDF membrane (Bio-Rad) using a
Trans-Blot Turbo (Bio-Rad), according to the manu-
facturer’s instructions, in transfer buffer (25 mM Tris, 192
mM glycine, 20% methanol, 0.05% SDS). Membranes were
then incubated in blocking buffer [TBST (20 mM Tris, 150
mM NaCl pH 7.4, 0.05% Tween- 20)], 5% (w/v) skim milk
powder (Diploma) for 1 h at RT, followed by incubation
with primary antibody overnight at 4 °C. Following mem-
brane washing in TBST for 4 × 15 min, membranes were
incubated with horse radish peroxidase (HRP)-conjugated
secondary antibodies for 1 h at RT. Membranes were then
washed in TBST for 4 × 10 min, followed by development
with Enhanced Chemiluminescence reagent (Pierce Che-
mical Co., Rockford, IL, USA). Fuji LAS4000 System (GE
Healthcare) or ChemiDoc MP (Bio-Rad) were used for
detecting luminescence signals.
DNA content analysis
DNA content analysis was performed as described pre-
viously [14]. Briefly, harvested cells were washed with ice-
cold 1X PBS followed by fixation in 70% ice-cold ethanol
in PBS. Fixed cells were incubated overnight at −20 °C.
Cells were centrifuged at 1200 rpm for 5 min then resus-
pended in 2 mL 1X PBS for rehydration. Cells were cen-
trifuged a second time and pellets resuspended in 1 mL
0.25% Triton X-100 (Sigma-Aldrich) in PBS. Following a
final centrifugation step, cell pellets were resuspended in
400 µL staining solution [25 µg/mL propidium iodide
(Sigma-Aldrich), 40 µg/mL RNase A (Sigma-Aldrich)] and
incubated for 2 h at room temperature in the dark. The
stained cells were stored at 4 °C until flow cytometric
analysis on a Fortessa (BD Biosciences). For data in Fig.
5b, Fig. 6b and Supplementary Fig. S7b, approximately
25 000 cells were anlased and the percentage of polyploid
cells (>4N) was calculated using FACS Express 6 cell cycle
analysis module.
Cell death and viability assay
For cell death assays, WT or Casp2−/− immortalised MEFs
[11] were co-transfected with GFP-caspase-2-WT, -S384A
or -S384E and β-gal expressing plasmids. After 24 h, cells
were fixed and incubated with an X-gal containing solution.
Blue (transfected) cells were counted for apoptotic
morphology with a stereomicroscope (Nikon, Tokyo,
Japan). At least 300–400 cells were counted in at least 20
different fields for each construct. Cell viability was deter-
mined using the MTS assay. Briefly, cells were seeded in
triplicate at 5000 cells per well in 50 µL complete culture
media in a 96-well microplate (BD Biosciences) and cul-
tured overnight at 37 °C with 10% CO2. Culture medium
(50 µL) containing DMSO or 200 nM BI2536 was added,
followed by 48 h incubation at 37 °C with 10% CO2.
Twenty-five microliters of MTS/PMS (96:4) reagent was
added to each well. The plate was then incubated in a
humidified, 10% CO2 incubator for 4 h, followed by reading
absorbance at 490 nm using a FLUOstar Omega (BMG
Labtech, Ortenberg, Germany). Control wells (no cells),
were used to detect the cell-free background absorbance.
In vitro kinase assay
In vitro kinase assays were performed as described pre-
viously [57]. Proteins were incubated with 38 ng of Aurora
B kinase (PV6130 Life Technologies) or 125 ng of Aurora
A kinase (PV3612 Life Technologies), 0.1 mM ATP
(Sigma-Aldrich), 5 μCi of [γ-32P]-ATP (3000 Ci/mmol,
10 mCi/mL) (PerkinElmer, Waltham, MA, USA) in kinase
buffer (20 mM HEPES [pH 7.5], 2 mM MgCl2, 1 mM DTT)
in a final reaction volume of 12.5 μL. After 30 min incu-
bation at 30 °C with constant agitation, 12.5 μL of 2x
Laemmli sample buffer were added to stop the reaction.
Samples were heated for 10 min at 90 °C and loaded on a
4–20% Tris-Glycine Precast Gel (Thermo Fisher Scientific).
Protein was transferred onto a nitrocellulose membrane
using the iBlot Dry Blotting System. Membranes were then
exposed to Kodak BioMax XAR Films (Sigma-Aldrich) at
−80 °C. The membranes were then blocked and subjected
to IB for GST.
Statistical analysis
The data are presented as mean ± standard error of the mean
(SEM) and were considered statistically significant when
p < 0.05. A two-sided Student’s t test was used to analyse
differences between data groups unless otherwise stated. All
statistical analyses were conducted using GraphPad Prism,
Version 6.05 (GraphPad, supplied by University of South
Australia; GraphPad Inc., CA, USA).
Data availability
The mass spectrometry proteomics data have been depos-
ited to the ProteomeXchange Consortium via the PRIDE
[58] partner repository with the dataset identifier
PXD017866, and are available via ProteomeXchange.
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